Ipca Laboratories UK Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Ipca Laboratories UK Limited Pharmaceutical Import Records from India — 6 Products, $21.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ipca Laboratories UK Limited — Pharmaceutical Importer Profile (2026) | 6 Products, $21.9M Trade | TransData Nexus

Ipca Laboratories UK Limited

Pharmaceutical Importer · United Kingdom · Lipid & Metabolism Focus · $21.9M Total Trade · DGFT Verified

Ipca Laboratories UK Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $21.9M across 6 products in 4 therapeutic categories. Based on 764 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Ipca Laboratories UK Limited sources from 1 verified Indian supplier, with Ipca Laboratories Limited accounting for 100.0% of imports.

Ipca Laboratories UK Limited — Import Portfolio & Supplier Network

Ipca Laboratories UK Limited import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ipca Laboratories UK Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ipca Laboratories Limited	$10.5M	973	100.0%

Ipca Laboratories UK Limited sources from 1 verified Indian supplier across 731 distinct formulations. The sourcing is highly concentrated — Ipca Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Ipca Laboratories UK Limited Import?

Formulation	Value	Ships
Harmless medicines: hydroxychloroquine	$400.3K	14
Paracetamol 500MG tablets(187365x10x10's	$200.0K	4
Paracetamol 500MG tablets(420107x10x10'spack =42010700 tablets	$150.0K	3
Hydroxychloroquine sulfate 200MG Film-Coated tablets(115265x6x10's Pack =6915900tablets)	$150.0K	3
Paracetamol 500MG tablets(279041x10x10'spack =27904100 tablets	$136.3K	3
Paracetamol 500MG tablets(233861x10x10'spack =23386100 tablets	$119.3K	3
Paracetamol 500MG tablets(233465x10x10'spack =23346500 tablets	$117.1K	3
Amlodipine 5MG tablets(1026820x2x14's Pack =28750960 tablets	$108.3K	3
Hydroxychloroquine sulfate 200MG	$100.3K	7
Paracetamol 500MG tablets(230267x10x10's	$100.0K	2
Paracetamol 500MG tablets(279785x10x10's	$100.0K	2
Allopurinol 100MG tablets535569x2x14'spack =14995932	$100.0K	2
Paracetamol 500MG tablets372365x10x10'spack =37236500	$100.0K	2
Amlodipine 10MG tablets(310064x2x14's Pack =8681792 tablets)	$100.0K	2
Amlodipine 10MG tablets(624519x2x14's Pack =17486532 tablets	$97.9K	3

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Allopurinol	Lipid & Metabolism	$7.1M	203	1.5%	4
2	Paracetamol	Analgesics & Antipyretics	$3.5M	69	1.0%	7
3	Bisoprolol	Cardiovascular	$3.1M	273	3.6%	4
4	Amlodipine	Cardiovascular	$3.0M	109	0.0%	17
5	Chloroquine	Antimalarial & Antiparasitic	$2.6M	55	1.5%	4
6	Hydroxychloroquine	Antimalarial & Antiparasitic	$2.6M	55	1.9%	3

Ipca Laboratories UK Limited imports 6 pharmaceutical products across 4 categories into United Kingdom totaling $21.9M.

Ipca Laboratories UK Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ipca Laboratories UK Limited, established on 4 November 2003, is a private limited company headquartered in Sunderland, Tyne and Wear, United Kingdom. The company operates as a pharmaceutical importer and buyer, specializing in the procurement of finished pharmaceutical formulations from India. It serves as a conduit for Ipca Laboratories Limited, its parent company based in Mumbai, India, facilitating the distribution of a diverse range of pharmaceutical products within the UK market. This strategic positioning enables Ipca Laboratories UK Limited to leverage its parent company's extensive manufacturing capabilities and product portfolio, thereby enhancing its role in the UK's pharmaceutical supply chain.

2Distribution Network

Ipca Laboratories UK Limited's distribution network is centered around its facility at Units 97-98 Silverbriar, Sunderland Enterprise Park East, Sunderland, SR5 2TQ. While specific details regarding additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic location in Sunderland positions it advantageously for distribution across the United Kingdom. The proximity to major transportation hubs facilitates efficient logistics operations, ensuring timely delivery of pharmaceutical products to various regions within the UK. This centralized distribution approach underscores the company's commitment to maintaining a robust and responsive supply chain.

3Industry Role

In the United Kingdom's pharmaceutical supply chain, Ipca Laboratories UK Limited functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from its parent company, Ipca Laboratories Limited in India, the UK subsidiary plays a pivotal role in introducing a diverse array of pharmaceutical products to the UK market. This role is crucial in meeting the demand for various therapeutic categories, thereby contributing to the overall healthcare landscape in the UK. The company's operations are characterized by a focus on quality assurance and regulatory compliance, ensuring that all imported products adhere to the stringent standards set by UK regulatory authorities.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ipca Laboratories UK Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ipca Laboratories UK Limited exhibits a high degree of sourcing concentration, with 100% of its pharmaceutical imports originating from a single supplier: Ipca Laboratories Limited in India. This exclusive sourcing arrangement indicates a strategic partnership that likely offers benefits such as favorable pricing, consistent product quality, and streamlined logistics. However, this single-source dependency also introduces potential risks, including vulnerability to supply chain disruptions, geopolitical factors, and regulatory changes in the supplier's country. The stability of this relationship is evidenced by the substantial volume of imports—764 shipments valued at $21.9 million USD over the period from 2022 to 2026—suggesting a robust and dependable partnership. Nonetheless, the lack of diversification in sourcing could pose challenges in mitigating risks associated with supply chain interruptions or changes in the supplier's operational status.

2Supply Chain Resilience

The resilience of Ipca Laboratories UK Limited's supply chain is closely tied to its exclusive sourcing from Ipca Laboratories Limited in India. While this arrangement ensures consistency in product quality and availability, it also means that the UK subsidiary is highly dependent on the operational stability and regulatory compliance of its Indian supplier. The absence of backup suppliers or alternative sourcing options could pose challenges in the event of supply chain disruptions, such as natural disasters, political instability, or regulatory changes in India. Additionally, the limited diversity in imported formulations—731 unique formulations over the same period—may restrict the company's ability to adapt to changing market demands or therapeutic trends. To enhance supply chain resilience, Ipca Laboratories UK Limited might consider exploring additional supplier relationships or diversifying its product portfolio to mitigate potential risks associated with over-reliance on a single source.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The MHRA is responsible for ensuring that medicines and medical devices meet appropriate standards of safety, quality, and efficacy before they are made available to the public. Key legislation governing pharmaceutical imports includes the Human Medicines Regulations 2012, which consolidates various legislative instruments related to the importation, manufacture, and distribution of human medicines. The marketing authorization pathway for Indian generics involves obtaining a Marketing Authorization (MA) from the MHRA, which grants the holder the right to market a specific medicinal product in the UK. This process includes a thorough evaluation of the product's quality, safety, and efficacy data, as well as compliance with Good Manufacturing Practice (GMP) standards. Additionally, the MHRA provides guidance on sourcing medicines for the UK market, outlining the requirements for importing authorized and unlicensed medicines, as well as the necessary licenses and authorizations. (gov.uk)

2Import Licensing & GMP

To import human medicines into the United Kingdom, companies must obtain specific licenses and ensure compliance with Good Manufacturing Practice (GMP) standards. The primary licenses required include:

Ipca Laboratories UK Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ipca Laboratories UK Limited's product strategy focuses on importing finished pharmaceutical formulations across multiple therapeutic categories, including Lipid & Metabolism, Cardiovascular, and Antimalarial & Antiparasitic. The company's portfolio is heavily concentrated, with the top five products accounting for 88% of the total import value. This concentration suggests a strategic emphasis on high-demand, high-value products within these therapeutic areas. The substantial import values for products like Allopurinol, Paracetamol, Bisoprolol, Amlodipine, and Chloroquine indicate a targeted approach to meet prevalent health concerns in the UK, such as cardiovascular diseases, metabolic disorders, and malaria. The market demand for these products is driven by their widespread use in treating chronic conditions and infectious diseases, necessitating a reliable supply of quality-assured medications.

2Sourcing Profile

Ipca Laboratories UK Limited's sourcing strategy is characterized by exclusive procurement from its parent company, Ipca Laboratories Limited in India. This approach ensures consistency in product quality and availability, leveraging the established manufacturing capabilities and regulatory compliance of the parent company. The focus on finished pharmaceutical formulations aligns with the company's objective to provide ready-to-market products

Frequently Asked Questions — Ipca Laboratories UK Limited

What products does Ipca Laboratories UK Limited import from India?

Ipca Laboratories UK Limited imports 6 pharmaceutical products across 4 categories. Top imports: Allopurinol ($7.1M), Paracetamol ($3.5M), Bisoprolol ($3.1M), Amlodipine ($3.0M), Chloroquine ($2.6M).

Who supplies pharmaceuticals to Ipca Laboratories UK Limited from India?

Ipca Laboratories UK Limited sources from 1 verified Indian suppliers. The primary supplier is Ipca Laboratories Limited (100.0% of imports, $10.5M).

What is Ipca Laboratories UK Limited's total pharmaceutical import value?

Ipca Laboratories UK Limited's total pharmaceutical import value from India is $21.9M, based on 764 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ipca Laboratories UK Limited focus on?

Ipca Laboratories UK Limited imports across 4 categories. The largest: Lipid & Metabolism (32.6%), Cardiovascular (27.6%), Antimalarial & Antiparasitic (24.1%).

Get Full Ipca Laboratories UK Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.